Treprostinil

Treprostinil is a potent prostacyclin vasodilator used to treat pulmonary arterial hypertension (PAH) by dilating blood vessels in the lungs and improving exercise capacity.

Dosage for Treprostinil is highly individualized and requires careful titration by a specialist in pulmonary hypertension.

Parenteral (Subcutaneous or Intravenous) Infusion

For patients new to prostacyclin therapy, the initial infusion rate is typically 1.25 ng/kg/min. If this initial dose is not tolerated, the rate may be reduced to 0.625 ng/kg/min. Healthcare providers will then increase the dose based on clinical response and tolerability, usually in increments of 1.25 ng/kg/min per week for the first four weeks, and then by 2.5 ng/kg/min per week for the remainder of the treatment. Many patients achieve an optimal maintenance dose between 40 ng/kg/min and 80 ng/kg/min, though some may require higher doses.

Inhaled Solution

The initial dose of inhaled Treprostinil is 3 breaths (18 mcg) per treatment session, administered four times daily during waking hours. Sessions should be spaced approximately 4 hours apart. The dose is typically increased by an additional 3 breaths per session every 1 to 2 weeks, with a target maintenance dose of 9 to 12 breaths (54–72 mcg) four times daily.

Oral Extended-Release Tablets

The starting dose for patients not currently on a prostacyclin is 0.125 mg three times daily (TID) or 0.25 mg twice daily (BID). Doses are increased by 0.125 mg TID or 0.25–0.5 mg BID every 3 to 4 days. The goal is to reach a dose that maximizes clinical benefit while minimizing side effects such as headache and nausea.

Treprostinil is not currently FDA-approved for use in pediatric patients. While some specialists may use Treprostinil off-label in children with severe PAH, safety and efficacy have not been formally established in clinical trials for patients under the age of 18. Pediatric dosing, when performed, is usually calculated based on body weight and closely follows adult titration protocols under intense medical supervision.

Renal Impairment

No specific dosage adjustments are required for patients with renal impairment, as Treprostinil is primarily cleared by hepatic metabolism. However, because metabolites are excreted renally, patients with severe renal disease should be monitored closely for unexpected side effects.

Hepatic Impairment

Treprostinil is extensively metabolized by the liver. For parenteral use in patients with mild-to-moderate hepatic impairment, the initial dose should be decreased to 0.625 ng/kg/min and increased cautiously. For the oral form (Orenitram), it is contraindicated in patients with severe hepatic impairment (Child-Pugh Class C). In mild hepatic impairment (Child-Pugh Class A), the starting dose is 0.125 mg BID with cautious titration. In moderate impairment (Child-Pugh Class B), the starting dose is 0.125 mg once daily.

Elderly Patients

Clinical studies did not include sufficient numbers of patients aged 65 and over to determine if they respond differently than younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function.

Parenteral Administration

Subcutaneous infusion is delivered via a small catheter inserted under the skin, usually in the abdomen or thigh. Intravenous infusion requires a central venous catheter. Both require a dedicated infusion pump. Patients must be trained on sterile technique, pump programming, and troubleshooting alarms.

Inhaled Administration

Use only the manufacturer-specified nebulizer or dry powder inhaler. The solution should not come into contact with the eyes or skin. Clean the device daily as instructed to prevent infection and ensure proper dosing.

Oral Administration

Orenitram tablets must be swallowed whole. Do not crush, split, or chew them, as this destroys the extended-release mechanism and can lead to a dangerous rapid release of the drug. Take with food to increase absorption and reduce stomach upset.

If a dose of oral Treprostinil is missed, take it as soon as possible with food. If it is almost time for the next dose, skip the missed dose and resume the regular schedule. Do not double the dose. For inhaled Treprostinil, if a session is missed, resume the next session as scheduled. For parenteral infusion, a missed dose is a medical emergency; if the pump stops or the catheter is dislodged, contact your medical team immediately to avoid rebound PAH.

Symptoms of Treprostinil overdose include flushing, headache, hypotension (low blood pressure), nausea, vomiting, and diarrhea. In the event of an overdose, the infusion should be slowed or stopped, and supportive care should be initiated to manage blood pressure and hydration. Seek emergency medical attention immediately if an overdose is suspected.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop the medication without direct medical guidance, as sudden changes can lead to a life-threatening worsening of your condition.

Side effects of Treprostinil are largely related to its pharmacological action as a potent vasodilator and are often dose-dependent. The most frequently reported side effects include:

• Infusion Site Pain and Reaction (Subcutaneous): This is the most common side effect for those using the subcutaneous route, occurring in up to 85% of patients. It involves redness, swelling, and significant pain at the site where the catheter enters the skin. While usually manageable, it can be severe enough to require a transition to intravenous delivery.
• Headache: A result of systemic vasodilation, these headaches can range from mild to throbbing and usually occur during the titration phase.
• Diarrhea and Nausea: Gastrointestinal upset is common, particularly with the oral form (Orenitram). Taking the medication with food can help mitigate these effects.
• Jaw Pain: Often described as a sharp pain or ache when taking the first bite of food, this is a classic prostacyclin-related side effect.

Treprostinil is a high-alert medication that requires specialized management. It should only be prescribed by physicians experienced in the diagnosis and treatment of Pulmonary Arterial Hypertension (PAH). Patients must be committed to the rigorous requirements of the therapy, including the maintenance of infusion pumps or the frequent daily dosing required for inhaled and oral forms. The most critical safety aspect of Treprostinil therapy is the prevention of treatment interruption, particularly for the parenteral (IV/SC) forms.

No FDA black box warnings for Treprostinil. However, the risk of rebound pulmonary hypertension due to abrupt withdrawal is considered a critical safety concern that carries similar weight in clinical practice.

• Abrupt Discontinuation: Avoid sudden interruption of Treprostinil. If the pump fails or the medication runs out, pulmonary hypertension symptoms may return with increased severity. Patients should be educated on how to recognize pump malfunctions and have a plan for emergency replacement.

While there are few absolute contraindications for drug combinations, the use of Treprostinil with strong CYP2C8 inhibitors (such as gemfibrozil) requires extreme caution and significant dose reduction. Gemfibrozil can increase the systemic exposure (AUC) of Treprostinil by approximately 2-fold, which significantly increases the risk of severe vasodilatory side effects and toxicity. If co-administration is unavoidable, the healthcare provider must reduce the Treprostinil dose.

• Anticoagulants and Antiplatelets: Drugs such as warfarin, heparin, dabigatran, clopidogrel, and aspirin increase the risk of bleeding when taken with Treprostinil. Since Treprostinil naturally inhibits platelet function, the combined effect can lead to major bleeding events. Patients should be monitored for signs of internal or mucosal bleeding.
• Antihypertensive Agents: Diuretics, ACE inhibitors, beta-blockers, and calcium channel blockers may have additive effects with Treprostinil, leading to symptomatic hypotension (excessively low blood pressure). Dose adjustments of the blood pressure medications may be necessary.

Treprostinil must NEVER be used in the following circumstances:

• Severe Hepatic Impairment (Oral Form): Orenitram is absolutely contraindicated in patients with Child-Pugh Class C hepatic impairment. Because the liver is the primary site of metabolism, severe dysfunction leads to dangerously high drug levels that the body cannot clear, resulting in profound toxicity.
• Hypersensitivity: Patients with a known allergy to Treprostinil or any of the excipients (inactive ingredients) in the specific formulation (e.g., metacresol in the injectable form) must not use the drug. Anaphylaxis, though rare, is a medical emergency.

These are conditions where the risk-benefit ratio must be carefully weighed by a specialist:

• Active Bleeding

Treprostinil is classified as Pregnancy Category B (under the old FDA system), meaning animal reproduction studies have failed to demonstrate a risk to the fetus, but there are no adequate and well-controlled studies in pregnant women. In clinical practice, PAH itself carries a very high risk of maternal and fetal mortality (up to 30-50%). Therefore, most specialists recommend continuing PAH therapy during pregnancy under the care of a high-risk obstetrician. Data from the REVEAL registry and other PAH databases suggest that while prostacyclins are used, patients must be monitored for fluid shifts and heart failure during the third trimester and delivery.

It is not known whether Treprostinil is excreted in human milk or what its effects might be on a nursing infant. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Treprostinil, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Safety and effectiveness in pediatric patients have not been established. Clinical use in children is generally limited to specialized centers. Pediatric patients may be more sensitive to the vasodilatory effects, and dosing must be meticulously adjusted for weight. There are no long-term data on the effects of Treprostinil on growth and development in children.

Treprostinil is a tricyclic benzindene analogue of prostacyclin (PGI2). Its primary mechanism of action is the direct activation of the prostacyclin (IP) receptor. Upon binding to the IP receptor on vascular smooth muscle cells, it stimulates the Gs-protein-adenylate cyclase pathway, increasing the production of cyclic adenosine monophosphate (cAMP). Increased cAMP leads to a decrease in intracellular calcium and promotes the relaxation of smooth muscle, resulting in potent vasodilation of the pulmonary and systemic arterial beds. Additionally, Treprostinil binds to IP receptors on platelets, increasing cAMP and inhibiting platelet activation and aggregation.

The hemodynamic effects of Treprostinil include a decrease in pulmonary vascular resistance (PVR), a decrease in mean pulmonary arterial pressure (mPAP), and an increase in cardiac index (CI) and mixed venous oxygen saturation (SvO2). These effects are dose-dependent. Unlike epoprostenol, Treprostinil is chemically stable at neutral pH and room temperature, which allows for a more consistent delivery profile. The onset of effect for IV/SC administration is nearly immediate, while the duration of effect after stopping an infusion is several hours, providing a wider safety margin than epoprostenol.